Related Experiment Videos

A fibroblast mitogen present in scleroderma but not control sera: inhibition by proteinase inhibitors

Insights

Scleroderma (SD) sera contain fibroblast mitogenic activity (MA) that increases fibroblast replication. Proteinase inhibitors block this MA, suggesting circulating proteinases may contribute to SD fibrosis.

Area of Science:

  • Connective tissue diseases
  • Dermatology
  • Immunology

Background:

  • Scleroderma (SD) is a fibrotic disease characterized by abnormal extracellular matrix deposition.
  • Fibroblast mitogenic activity (MA) has been observed in the sera of patients with scleroderma.

Purpose of the Study:

  • To investigate the role of fibroblast MA in scleroderma pathogenesis.
  • To determine if MA in scleroderma sera is mediated by proteinases.

Main Methods:

  • Human skin fibroblasts from control and scleroderma subjects were cultured.
  • Fibroblast replication was assessed after exposure to control or scleroderma sera.
  • The effect of proteinase inhibitors (STI and TLCK) on MA was evaluated.

Main Results:

  • Scleroderma sera significantly increased control fibroblast replication at 15% concentration.
  • Scleroderma fibroblasts showed only slight responsiveness to MA, even at 30% serum concentration.
  • Proteinase inhibitors completely abrogated the MA in scleroderma sera but not in control sera.

Conclusions:

  • Circulating proteinases with selective fibroblast mitogenic activity may contribute to the fibrotic process in scleroderma.
  • These findings suggest a potential mechanism for fibroblast dysregulation in scleroderma pathogenesis.

Related Concept Videos